Company profile

Ticker
ABT
Exchange
Website
CEO
Robert B. Ford
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
360698440

ABT stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

4 Nov 20
1 Dec 20
31 Dec 20

News

Quarter (USD) Sep 20 Jun 20 Mar 20 Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
24 Nov 20 William A Osborn Common shares without par value Option exercise Aquire M No 43.64 21,448 935.99K 79,745
24 Nov 20 William A Osborn Option Common shares Option exercise Aquire M No 43.64 21,448 935.99K 0
26 Oct 20 Robert E Funck Common shares without par value Sell Dispose S No 108.8279 83,333 9.07M 182,217
26 Oct 20 Robert E Funck Common shares without par value Option exercise Aquire M No 38.4 83,333 3.2M 265,550
26 Oct 20 Robert E Funck Option Common shares Option exercise Dispose M No 38.4 83,333 3.2M 0
1 Oct 20 Gregory A Ahlberg Common shares without par value Grant Aquire A No 0 1,490 0 8,016
1 Oct 20 Gregory A Ahlberg Option Common Shares Grant Aquire A No 109.36 9,084 993.43K 9,084
30 Sep 20 Alpern Robert J Stock Equivalent Units Common Shares Grant Aquire A No 108.83 72 7.84K 8,116
72.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2226 2181 +2.1%
Opened positions 165 189 -12.7%
Closed positions 120 99 +21.2%
Increased positions 831 863 -3.7%
Reduced positions 896 848 +5.7%
13F shares
Current Prev Q Change
Total value 140.5B 117.83B +19.2%
Total shares 1.29B 1.29B -0.4%
Total puts 7.13M 6.01M +18.7%
Total calls 7.11M 6.2M +14.6%
Total put/call ratio 1.0 1.0 +3.5%
Largest owners
Shares Value Change
Vanguard 148.16M $16.12B -1.3%
BLK Blackrock 135.02M $14.69B +0.2%
Capital Research Global Investors 87.41M $9.51B -0.0%
STT State Street 73.67M $8.02B -1.2%
Capital International Investors 55.98M $6.09B -1.3%
Wellington Management 35.01M $3.81B -2.6%
NTRS Northern Trust 27.03M $2.94B -0.0%
BAC Bank Of America 26.32M $2.86B +4.9%
Massachusetts Financial Services 25.72M $2.8B +5.0%
MS Morgan Stanley 25.37M $2.76B +2.3%
Largest transactions
Shares Bought/sold Change
MCQEF Macquarie 851.3K -6.5M -88.4%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 3.39M +2.88M +566.9%
Demars Financial 25.17K -2.49M -99.0%
GS Goldman Sachs 6.65M -2.13M -24.2%
GQG Partners 14.51M +1.98M +15.8%
Vanguard 148.16M -1.88M -1.3%
CIBC Private Wealth 3.94M +1.86M +89.2%
FMR 15.08M +1.82M +13.7%
1832 Asset Management 1.79M +1.78M +14472.3%
AMP Ameriprise Financial 13.37M +1.67M +14.3%

Financial report summary

?
Risks
  • The manufacture of many of Abbott’s products is a highly exacting and complex process, and if Abbott or one of its suppliers encounters problems manufacturing products, Abbott’s business could suffer.
Management Discussion
  • The increase in Total Net Sales in 2019 reflects volume growth across all of Abbott’s segments.  The increase in Total Net Sales in 2018 reflects the acquisition of Alere, as well as volume growth across all of Abbott’s segments.  The price declines related to the Medical Devices segment in 2019 and 2018 primarily reflect pricing pressures on drug eluting stents (DES) as a result of market competition in the U.S. and other major markets.
  • A comparison of significant product and product group sales is as follows.  Percent changes are versus the prior year and are based on unrounded numbers.
  • n/m = percent change is not meaningful.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: accuracy, AdviseDx, antigen, athletic, automatically, BinaxNOW, Biosensor, Card, efficacy, equated, IgM, immunoassay, Immunoglobulin, listing, portable, repaid, Sense, significantly, source, Sport, training, understand
Removed: IRS, paid

Patents

GRANT
Design
Analyte sensor device
1 Dec 20
Inventors: Louis Pace, Peter G. Robinson, Joel Goldsmith
GRANT
Utility
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers
1 Dec 20
Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or a moderate, severe, or moderate to severe traumatic brain injury (TBI), by detecting levels of cardiac troponin I (cTnI) and one or more early biomarkers which are not cTnI, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in biological samples taken from a human subject at time points within about 24 hours of injury after the subject has sustained or may have sustained the injury to the head.
GRANT
Utility
Paravalvular leak sealing mechanism
1 Dec 20
A collapsible and expandable stent body includes a generally tubular annulus section, one or more prosthetic valve elements mounted to the stent body, and a cuff attached to the stent body.
GRANT
Utility
Integrated sheath interface feature
1 Dec 20
A delivery device for an implantable medical device includes an inner shaft with a device-carrying region, an outer shaft surrounding the inner shaft, a sheath at a distal end of the outer shaft, and a sleeve.
GRANT
Utility
Introducer sheath having expandable portions
1 Dec 20
An introducer sheath (300) includes a body (305) extending between a leading end (304) and a trailing end (302) and including a plurality of rectangular segments (310) extending from the leading end to the trailing end.